The estimated Net Worth of Aktiengesellschaft Bayer Gl... is at least $256 Million dollars as of 5 January 2018. Aktiengesellschaft Gl owns over 527,472 units of CRISPR Therapeutics AG stock worth over $255,954,523 and over the last 7 years Aktiengesellschaft sold CRSP stock worth over $0.
Aktiengesellschaft has made over 1 trades of the CRISPR Therapeutics AG stock since 2018, according to the Form 4 filled with the SEC. Most recently Aktiengesellschaft bought 527,472 units of CRSP stock worth $11,999,988 on 5 January 2018.
The largest trade Aktiengesellschaft's ever made was buying 527,472 units of CRISPR Therapeutics AG stock on 5 January 2018 worth over $11,999,988. On average, Aktiengesellschaft trades about 527,472 units every 0 days since 2018. As of 5 January 2018 Aktiengesellschaft still owns at least 5,632,802 units of CRISPR Therapeutics AG stock.
You can see the complete history of Aktiengesellschaft Gl stock trades at the bottom of the page.
Aktiengesellschaft's mailing address filed with the SEC is KAISER WILHEM ALLEEENERGIEWEG 1, 3641 RT, , LEVERKUSENMIJDRECHT, 2MP7, 51368.
Over the last 8 years, insiders at CRISPR Therapeutics AG have traded over $284,003,967 worth of CRISPR Therapeutics AG stock and bought 3,347,446 units worth $53,410,590 . The most active insiders traders include Plc Gsk, Ali Behbahani und Corp /De/ Celgene. On average, CRISPR Therapeutics AG executives and independent directors trade stock every 13 days with the average trade being worth of $2,405,548. The most recent stock trade was executed by Julianne Bruno on 20 June 2024, trading 7,000 units of CRSP stock currently worth $318,080.
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
CRISPR Therapeutics AG executives and other stock owners filed with the SEC include: